Expression of the tumor suppressor gene p16, and lymph node metastasis in patients with ovarian cancer

Objective: To investigate the levels of plasma exosome-derived fragile-site associated tumor suppressor (FATS) and evaluate its predictive ability in ovarian cancer (OC) patients. Patients and Methods: Exosome-rich fractions were isolated from the plasma of enrolled 90 patients with OC. The levels of plasma exosome-derived FATS were detected with ELISA. Results: The levels of exosome-derived FATS in OC patient were significantly lower than in healthy controls (P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with low grade (1/2), FIGO stages I/II than high grade (3/4), stages III/ IV disease (P = 0.003; P < 0.001). The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis, no ascites than those with lymph node metastasis, ascites (both P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with CA-125 less than 35U/ml than more than 35U/ml (P < 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients who had low plasma exosome-derived FATS levels than that high levels (both P < 0.001). The AUROC of plasma exosome-derived FATS were 0.85(95% CI: 0.76-0.91) for 5-DFS, 0.91(95% CI: 0.83-0.96) for 5-OS prediction in patients with OC, respectively. Conclusions: Plasma exosome-derived FATS levels in OC patient were significantly down-regulated. Low levels of plasma exosome-derived FATS had close relationship with FIGO stages I/II, low grade, ascites, higher levels of CA-125, lymph node metastasis and prognosis of OC patients. Our findings may provide a new strategy in treating OC.

Download Full-text

Plasma Exosome-Derived Fragile-Site Associated Tumor Suppressor is a Powerful Predictor of Prognosis in Patients with Ovarian Cancer

10.21203/rs.3.rs-560273/v1 ◽

2021 ◽

Author(s):

Renjing Hu ◽

Xiaochun Chen ◽

Shiliang Zhang ◽

Bin Liu ◽

Hao Pei ◽

...

Keyword(s):

Ovarian Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Tumor Suppressor ◽

Fragile Site ◽

Predictive Ability ◽

Ca 125 ◽

Low Grade ◽

Node Metastasis ◽

Close Relationship

Abstract Objective: To investigate the levels of plasma exosome-derived fragile-site associated tumor suppressor (FATS) and evaluate its predictive ability in ovarian cancer (OC) patients.Patients and Methods: Exosome-rich fractions were isolated from the plasma of enrolled 90 patients with OC. The levels of plasma exosome-derived FATS were detected with ELISA.Results: The levels of exosome-derived FATS in OC patient were significantly lower than in healthy controls (P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with low grade (1/2), FIGO stages I/II than high grade (3/4), stages III/ IV disease (P = 0.003; P < 0.001). The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis, no ascites than those with lymph node metastasis, ascites (both P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with CA-125 less than 35U/ml than more than 35U/ml (P < 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients who had low plasma exosome-derived FATS levels than that high levels (both P < 0.001). The AUROC of plasma exosome-derived FATS were 0.85(95% CI: 0.76-0.91) for 5-DFS, 0.91(95% CI: 0.83-0.96) for 5-OS prediction in patients with OC, respectively.Conclusions: Plasma exosome-derived FATS levels in OC patient were significantly down-regulated. Low levels of plasma exosome-derived FATS had close relationship with FIGO stages I/II, low grade, ascites, higher levels of CA-125, lymph node metastasis and prognosis of OC patients. Our findings may provide a new strategy in treating OC.

Download Full-text

228 Predictive factors of lymph node involvement and topography of lymph node metastasis in patients with epithelial ovarian cancer

10.1136/ijgc-2020-igcs.195 ◽

2020 ◽

Author(s):

D Atallah ◽

M Moubarak ◽

B Dagher ◽

N Khalil ◽

N El Kassis ◽

...

Keyword(s):

Ovarian Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Epithelial Ovarian Cancer ◽

Predictive Factors ◽

Lymph Node Involvement ◽

Node Metastasis ◽

Node Involvement

Download Full-text

Association of serum autoantibodies to tumor-suppressor gene p53 in patients with ovarian cancer according to status of the disease

Oncology Reports ◽

10.3892/or.4.6.1157 ◽

1997 ◽

Author(s):

D Marx ◽

T Uebel ◽

A Schauer ◽

W Kuhn ◽

H Meden

Keyword(s):

Ovarian Cancer ◽

Tumor Suppressor ◽

Tumor Suppressor Gene ◽

Suppressor Gene ◽

Tumor Suppressor Gene P53

Download Full-text

Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer

Technology in Cancer Research & Treatment ◽

10.1177/1533033819896809 ◽

2019 ◽

Vol 18 ◽

pp. 153303381989680

Author(s):

Hongxiao Chen ◽

Xiufang Tian ◽

Yajing Luan ◽

Hui Lu

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Distant Metastasis ◽

Critical Region ◽

Noncoding Rna ◽

Digeorge Syndrome ◽

Region Gene ◽

Node Metastasis

Emerging evidence have indicated that dysregulated long noncoding ribonucleic acids act as a novel diagnostic and therapeutic target in the progression of ovarian cancer. Long noncoding RNA DiGeorge syndrome critical region gene 5 has been reported to participate in some types of human cancer progresses, but its clinical roles in ovarian cancer had been rarely reported. This study aimed to explore the expression, clinicopathological features, diagnostic, and prognostic values of DiGeorge syndrome critical region gene 5 in ovarian cancer. The total levels of DiGeorge syndrome critical region gene 5 transcript variant 1 (NR_002733.2) and 2 (NR_045121.1) in patients with ovarian cancer were determined by quantitative reverse transcription polymerase chain reaction. The correlation of DiGeorge syndrome critical region gene 5 expression with clinicopathological factors was statistically analyzed by χ2 test. Overall survival analysis was carried out with the Kaplan–Meier curves with the log-rank test. Univariate and multivariate Cox regression analyses were performed to identify the prognostic significance of DiGeorge syndrome critical region gene 5 expression. Receiver operating characteristic curves were constructed to estimate the diagnostic and prognostic usefulness of DiGeorge syndrome critical region gene 5 in ovarian cancer. Results showed that relative DiGeorge syndrome critical region gene 5 expression was reduced by 36.81% and 65.79% in ovarian cancer tissues of patients and Gene Expression Omnibus DataSets (GSE119056) in contrast to normal tissues, respectively. Patients with lymph node metastasis and distant metastasis exhibited lower levels of DiGeorge syndrome critical region gene 5 in contrast to those patients with non-lymph node metastasis and non-distant metastasis, respectively. Low expression of DiGeorge syndrome critical region gene 5 was significantly associated with large tumor size, more lymph node metastasis, present distant metastasis, advanced clinical stage, and short overall survival in patients with ovarian cancer. Low expression of DiGeorge syndrome critical region gene 5 was an independent unfavorable prognostic factor for overall survival in patients with ovarian cancer. Receiver operating characteristics curves for prognosis yielded significant area under curves for lymph node metastasis, clinical stage, and overall survival. In conclusion, our study demonstrated that downregulated DiGeorge syndrome critical region gene 5 may be a new promising biomarker for predicting clinical progression and prognosis in patients with ovarian cancer.

Download Full-text

Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation

Analytical Cellular Pathology ◽

10.1155/2019/4265040 ◽

2019 ◽

Vol 2019 ◽

pp. 1-7

Author(s):

Xuting Xu ◽

Dong Li ◽

Jin Liu ◽

Zhihong Ma ◽

Huilian Huang ◽

...

Keyword(s):

Lymph Node ◽

Lymph Node Metastasis ◽

Tumor Suppressor ◽

Cell Lines ◽

Western Blotting ◽

Invasion And Migration ◽

Node Metastasis ◽

Proliferation And Metastasis ◽

And Migration

Objective. The receptor-type tyrosine-protein phosphatase κ (PTPRK) is a candidate tumor suppressor involved in the tumorigenesis of various organs. However, its expression and biological roles in non-small-cell lung cancer (NSCLC) have not yet been investigated. Methods. PTPRK expression in NSCLC tissues and cell lines was examined using real-time PCR and western blotting. In addition, the effects of PTPRK on cell migration, invasion, and proliferation were evaluated in vitro. Furthermore, we explored whether the downregulation of PTPRK led to STAT3 activation in NSCLC cell lines by western blotting. The expression of phospho-STAT3Tyr705 in primary human NSCLC tissues was evaluated by immunohistochemistry. Results. The results showed that PTPRK expression was frequently reduced in NSCLC tissues with lymph node metastasis and cell lines. The inhibition of PTPRK expression resulted in increased proliferation, invasion, and migration of NSCLC cells in vitro. Additionally, after silencing of PTPRK, phospho-STAT3Tyr705 was significantly increased in NSCLC cells. Moreover, the phospho-STAT3Tyr705 levels of NSCLC tissues were positively correlated with lymph node metastasis and significantly inversely correlated with the expression of PTPRK (p<0.05). Conclusions. These results suggested that PTPRK functions as a novel tumor suppressor in NSCLC, and its suppressive ability may be involved in STAT3 activation.

Download Full-text